Dr Reddy's completes deal with Upsher-Smith Laboratories
22 July 2019 | News
Dr. Reddy’s Laboratories announces closure of the transaction to divest ZEMBRACE® SYMTOUCH® and TOSYMRATM to Upsher-Smith Laboratories
image credit- shuttershock.com
Dr. Reddy’s Laboratories Limited announces the closure of the transaction with Upsher-Smith Laboratories, LLC (Upsher-Smith), pursuant to the satisfactory completion of all customary closing conditions including the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act), as amended.
Under the agreement Dr. Reddy’s sold its US and select territory rights for ZEMBRACE® SYMTOUCH® (sumatriptan injection) 3 mg and TOSYMRATM (sumatriptan nasal spray) 10 mg, which were commercialized through its wholly owned subsidiary, Promius Pharma, LLC.
